



INDIAN PSYCHIATRIC SOCIETY

Headquarters : Plot 43, Sector 55, Gurgaon, Haryana 122 003, India
Phone: +91-124-4006750, **Email**: ipssecretaryoffice@gmail.com
Secretariat : NC -116, SBI Officers Colony, Kankarbagh, Patna – 800020, India
Mobile: +919431011775, **Email**: dr.vinaykr@gmail.com
Websites : www.indianpsychiatricsociety.org • www.indianjpsychiatry.org

[Estd: 1948]

Dr. Mrugesh Vaishnav

President

Samvedana Happiness Hospital
 3rd floor, Satya One Complex
 Helmet Circle, Memnagar
 Ahmedabad - 380006, Gujarat
T : +91 79-26764350
M : +91 9825767565
E : drmrugesh@rediffmail.com

Dr. P. K. Dalal

Vice President

Professor & Head, Department of
 Psychiatry, K. G. Medical University,
 Shah Mina Road, Chowk,
 Lucknow - 226003, Uttar Pradesh
T : +91 522 241 8529
M : +91 9415025665
E : docpkdalal@gmail.com

Dr. Vinay Kumar

Hon. General Secretary

NC-116, SBI Officers' Colony
 Kankarbagh,
 Patna - 800020, Bihar
T : +91 612 2353882
M : +91 9431011775
 +91 9631144236
E : dr.vinaykr@gmail.com

Dr. Mukesh P. Jagiwal

Hon. Treasurer

101, 'Shriji Niwas', A to Z Bldg.
 Opp. Dhiraj Sons
 Mansukh Tower Lane, Athwagate
 Surat - 395001, Gujarat
T : +91 6352779966
M : +91 9879521795
E : mukeshjagiwala@yahoo.co.in

Dr. Om Prakash Singh

Hon. Editor

AA 304, Ashabari Apartments
 O/31, Baishnabghata
 Patuli Township,
 Kolkata - 700094, West Bengal
T : +91 8768781046
M : +91 9434013231
E : opsingh.nm@gmail.com

EXECUTIVE COUNCIL (2019-20)

Imm. Past President

Dr. Ajit V. Bhide

M : +91 9243115266

Imm. Past Hon. Gen. Secretary

Dr. Gautam Saha

M : +91 9830055235

Imm. Past Hon. Treasurer

Dr. Mukesh P. Jagiwal

M : +91 9227926688

DIRECT COUNCIL MEMBERS

Dr. Abdul Majid

M : +91 9419071771

Dr. Harpreet Singh

M : +91 7702486770

Dr. Kishor Gujar

M : +91 9922501577

Dr. Neelanjana Paul

M : +91 9433831692

Dr. Abhay Matkar

M : +91 9448450565

Dr. M. Aleem Siddiqui

M : +91 7607358897

Dr. Laxmikant Rath

M : +91 9823077550

Dr. Savita Malhotra

M : +91 9872000894

Dr. Shashi Rai

M : +91 9415007076

ZONAL REPRESENTATIVES

Central Zone

Dr. Rajeev Jain

M : +91 9826097055

Dr. Vipul Singh

M : +91 9415051675

Eastern Zone

Dr. Srikumar Mukherjee

M : +91 9830029598

Dr. Tophan Pati

M : +91 9437064922

Northern Zone

Dr. B. S. Shekhawat

M : +91 9414069655

Dr. Parshotam Dass Garg

M : +91 9872622889

Southern Zone

Dr. Gunapalli Suresh Kumar

M : +91 9848608604

Dr. Laxmi Naresh Vadlamani

M : +91 9348039580

Western Zone

Dr. Arun V. Marwale

M : +91 7588402283

Dr. Vivek C. Kirpekar

M : +91 9822200689

IPS/Position Statement-3/25.09.2019

Position Statement on Use of Buprenorphine for treatment for Opioid Dependence

The Indian Psychiatric Society:

- *Recognizes* that Opioid Dependence is a significant public health challenge in India, as reported by the Government of India in its recent report – Magnitude of Substance Use in India¹.
- *Realizes* that Opioid Dependence is a chronic, relapsing disorder which requires a long-term treatment¹.
- *Agrees* with World Health Organization (WHO), United Nations Office on Drugs and Crime (UNODC)¹, International Narcotics Control Board (INCB)¹ and many other International and National agencies¹ which have recommended long-term treatment with opioid agonists like Buprenorphine as the most effective treatment option including for patients in a developing country like India.
- *Recognizes* that Buprenorphine is a controlled medication under the United Nations Drug control conventions as well as under the Indian Narcotic Drugs & Psychotropic Substances (NDPS) Act 1985. In addition, this medicine has been placed in the Essential Medicine List by the WHO.
- *Agrees* that all possible steps must be taken to minimize the diversion and misuse of this medication while ensuring that it remains accessible to lakhs of affected patients in India.
- *Expresses* concern that as per the recent data, there are lakhs of patients of opioid dependence in India who do not have access to evidence-based, effective, safe and affordable treatment, major reason for which is the restrictive legal and policy environment¹.
- *Welcomes* the recommendation made by the Subject Expert Committee (SEC) of Central Drug Standards Control Organization (CDSCO), Ministry of Health and Family Welfare (MoH&FW), Government of India dated 8 August 2018 that buprenorphine 'should be allowed to be supplied to psychiatric hospitals, clinics instead of the earlier condition that drug should be supplied to de-addiction centers only'¹.
- *Assures* that IPS will encourage, guide and facilitate its members and other treatment providers in India to provide evidence based treatment, with procedures fully compliant with the laws and policies, through various means including through educational / professional developmental activities as well as through tools like practice guidelines, treatment guidelines and standard procedures.

Dr. Vinay Kumar

Hon. General Secretary
 Indian Psychiatric Society

Dr. Mrugesh Vaishnav

President
 Indian Psychiatric Society

¹ Ambekar A, Agrawal A, Rao R, Mishra AK, Khandelwal SK, Chadda RK on behalf of the group of investigators for the National Survey on Extent and Pattern of Substance Use in India (2019). *Magnitude of Substance Use in India*. New Delhi: Ministry of Social Justice and Empowerment, Government of India

¹ World Health Organization (WHO). Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. 2009; Geneva: WHO

¹ WHO/UNODC/UNAIDS position paper. Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention, 2004

¹ INCB 2017. Treatment, rehabilitation and social reintegration for drug use disorders: essential components of drug demand reduction. Annual Report 2017.

¹ Ambekar A & Goyal S (2014), "Clinical Practice Guidelines for treatment of Opioid Use Disorders", in Basu D, Dalal PK (eds), Clinical Practice Guidelines for Substance Use Disorders, New Delhi: Indian Psychiatric Society

¹ Ambekar A, Murthy P, Basu D, Rao GP & Mohan A. (2017) "Challenges in the scale-up of Opioid Substitution Treatment (OST) in India" (Guest Editorial), Indian Journal of Psychiatry;59:6-9

¹ CDSCO. Recommendation of the SEC made in its 38th meeting held on 8/8/2018 at CDSCO HQ, New Delhi. Available at <https://cdsco.gov.in/opencms/opencms/en/Committees/SEC/>